Citigroup’s Amylyx Pharmaceuticals AMLX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q1
Sell
-71,700
Closed -$1.06M 5624
2023
Q4
$1.06M Buy
71,700
+13,500
+23% +$207K ﹤0.01% 2779
2023
Q3
$1.07M Sell
58,200
-2,500
-4% -$52.9K ﹤0.01% 2453
2023
Q2
$1.31M Buy
60,700
+55,700
+1,114% +$1.5M ﹤0.01% 2616
2023
Q1
$147K Sell
5,000
-48,100
-91% -$1.67M ﹤0.01% 3885
2022
Q4
$1.96M Sell
53,100
-20,600
-28% -$731K ﹤0.01% 2051
2022
Q3
$2.08M Buy
+73,700
New +$1.84M ﹤0.01% 2114

Other funds holding AMLX

Citigroup's AMLX Position: Q2 2026 in Review

Citigroup increased its Amylyx Pharmaceuticals (AMLX) stake by 116% in Q2 2026, buying an estimated $571K and bringing the position to 68,684 shares worth $1.23M. The position accounts for ﹤0.01% of the portfolio, ranked #3297.

Citigroup first reported a position in AMLX in Q1 2022 and has held it in 18 quarters since. The position peaked at $5.71M in Q4 2023. 206 funds tracked by Wall St. Rank hold AMLX as of Q2 2026.

  • Citigroup held 68,684 shares of Amylyx Pharmaceuticals worth $1.23M as of Q2 2026.
  • Citigroup bought 36,902 Amylyx Pharmaceuticals shares in Q2 2026, an estimated $571K.
  • Amylyx Pharmaceuticals made up ﹤0.01% of Citigroup's portfolio in Q2 2026, its #3297 holding.
  • Citigroup first reported a position in Amylyx Pharmaceuticals in Q1 2022 and has held it in 18 quarters since.
  • Citigroup's Amylyx Pharmaceuticals position peaked at $5.71M in Q4 2023.
  • 206 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q2 2026.

Based on Citigroup's 13F filing for Q2 2026, filed 3 Aug 2026.